



8th May 2024

Circular 006/24

RE: Medicines Management Programme (MMP) Best-Value Medicines - Teriparatide

Dear Pharmacist,

Please find enclosed a copy of a letter issued to prescribing consultants by the HSE Medicines Management Programme (MMP) in relation to Best-Value Medicines (BVMs): Teriparatide under the High Tech Arrangement. I refer to the previous communication in this regard (Pharmacy Circular 011/23) that includes supporting FAQs.

The MMP has identified an additional BVM for teriparatide; Tetridar®. Therefore, from 1 May 2024, the MMP recommends the following BVMs for teriparatide:

- Movymia®
- Sondelbay®
- Tetridar®

Further resources are available on the MMP website (www.hse.ie/mmp) in the section entitled '*Best-value medicines*'.

Yours faithfully,

Shaun Flanagan
Assistant National Director
Primary Care Reimbursement Service

Re: Best-Value Medicines; Teriparatide

30 April 2024

Dear Colleagues,

The purpose of this letter is to:

- Inform you of an addition to the best-value medicines (BVMs) for teriparatide
- Update you on the uptake of the BVMs for teriparatide
- Thank you and your team for your efforts in assisting the Health Services by prescribing the BVMs for teriparatide
- Request that all patients who remain on a non-BVM be switched to a BVM, where possible.

Teriparatide

The HSE-Medicines Management Programme (MMP) has identified an additional BVM for teriparatide; **Tetridar**[®]. The evaluation report for this medicine is available on the MMP website (www.hse.ie/mmp) in the section entitled *Best-value medicines*.

Therefore, from 1 May 2024, the MMP recommends the following BVMs for teriparatide:

- **Movymia**[®]
- **Sondelbay**[®]
- **Tetridar**[®].

BVM Uptake

Since the implementation of the BVM recommendations in March 2023, there has been a significant increase in the prescribing of the BVMs. In March 2024, 68% of patients in receipt of teriparatide on the High Tech Arrangement were prescribed a BVM.

I would like to take this opportunity to thank you and your colleagues for embracing the MMP recommendations in relation to the BVMs for teriparatide. The commitment of you and your team to prescribing the BVMs is leading to savings for the health service. This reduces the financial burdens on the HSE arising out of the funding of reimbursed medicines, and can assist in facilitating access to new, innovative medicines for patients.

Non-BVMs

Non-BVMs for teriparatide (i.e. Forsteo[®], Terrosa[®]) are more expensive than the recommended BVMs (**Movymia**[®], **Sondelbay**[®], **Tetridar**[®]). As of March 2024, approximately 500 patients remain in receipt of the non-BVMs for teriparatide on the High Tech Arrangement.

All patients who are currently prescribed a non-BVM (i.e. Forsteo[®], Terrosa[®]) should be switched to a BVM, where possible.

High Tech Hub Enhancement

The High Tech Hub has been enhanced to support clinical teams to identify patients who remain on non-BVMs. A search function has been added to the *My Patients* tab; this allows clinical teams to search for prescriptions generated on the High Tech Hub by INN or medicinal product within a specified timeframe. This will facilitate timely identification of patients who remain on a non-BVM.

A step-by-step guide on how to use this search function to identify patients who remain on a non-BVM is included with this communication.

Further information on the BVM initiative including information for healthcare professionals, and resources to support initiating patients on, or switching them to the BVMs are available on the MMP website (www.hse.ie/mmp) in the section entitled *Best-value medicines*. Please contact the MMP (mmp@hse.ie) if you have any queries in relation to the BVMs.

Given the significant financial challenges facing the Health Service this year, it is vital that prescribing of the BVMs is optimised. I would ask that you continue to support this important initiative, which helps to secure ongoing access for patients to new and innovative medicines.

With best wishes,



Professor Michael Barry,
National Clinical Lead,
HSE-Medicines Management Programme.